Document is current

Article History

Received: 17 December 2024

Accepted: 16 July 2025

First Online: 6 August 2025

Declarations

:

: This study was conducted in compliance with the Declaration of Helsinki and was approved by the institutional review boards or independent ethics committees at each site. All patients provided written informed consent prior to participation in any study-related activities.

: E.L.M. reports having received personal honoraria from AstraZeneca, Seagen, Lilly and Daichii Sankyo; having received personal honoraria for advisory board participation from AstraZeneca, Daichii Sankyo and Seagen; having received personal speakers’ bureaus from Lilly and AstraZeneca; having personal support for attending meetings and/or travel from Gilead and Roche. J.M.P.G. reports having received personal honoraria for advisory board participation from Lilly, Roche, Eisai, Daichii Sankyo, AstraZeneca, Seattle Genetics, MSD, and Gilead; having personal support for attending meetings and/or travel from Roche; being an employee at MEDSIR. M.G. reports having received honoraria from Novartis, Gilead, Astra Zeneca, Pfizer; having personal support for attending meetings and/or travel from Roche, Pfizer, Astra Zeneca, Gilead; having received honoraria for advisory board participation from Gilead, Novartis, AstraZeneca, Pfizer. N.R. reports having received personal speakers’ bureaus from Novartis, Pfizer, Daichii-AstraZeneca, Lilly and Gilead; having received institutional financial support from Pfizer. M.M.G. reports having received personal honoraria for consulting, advisory or speaker fees from Gilead, Novocure, Seagen, Boehringer Ingelheim, Roche, Celgene, Lilly Astra Zeneca-Daiichi sankyo, Reddy Pharma Iberia; having personal support for attending meetings and/or travel from Pfizer, Gilead and Roche; having received institutional financial support from Pfizer and Roche. S.G.S reports having received personal honoraria for advisory board participation from AstraZeneca; having received personal speakers’ bureaus from Novartis; having personal support for attending meetings and/or travel from Pfizer. B.B. reports having received personal honoraria for medical edication as consulting or advisory board from MSD, Roche, Pierre Fabre, Novartis, AstraZeneca and Seagen; having received personal speakers’ bureaus from Pfizer, Roche, MSD, Palex, Eisai, Daichii Sankyo/AstraZeneca and Seagen. S.M. having personal support for attending meetings and/or travel from AstraZeneca, Daiichi Sankyo, Gilead, Lilly, Novartis, MSD,and Pfizer; having received institutional financial support from Lilly. L.G. reports having received personal speakers’ bureaus from Novartis and Daichii Sankyo. M.F.P. is a full-time employee at MEDSIR; S.G.V. is a full-time employee at MEDSIR; A.G.S is a full-time employee at MEDSIR; A.M.M.is a full-time employee at MEDSIR; O.B.S. is a full-time employee at MEDSIR; D.A.L. is a full-time employee at MEDSIR. A.L.C reports having received institutional financial support from Roche, Agendia, Lilly, Pfizer, Novartis, Merck Sharp & Dohme, Gilead, and Daichii-Sanyo; having received personal honoraria for consulting/advisory from Lilly, Roche, Pfizer, and Novartis; having received personal speakers’ bureaus from Lilly, AstraZeneca, MSD, Pfizer and Novartis; having personal support for attending meetings and/or travel from Roche, Pfizer, AstraZeneca, Steamline therapeutics and MSD; stock or other ownership of MEDSIR and MAJ3 Capital & Initia-Research; and patents: Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy. Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/0338368 A1. LICENSED. J.C reports having received personal honoraria for consulting/advisory from AstraZeneca, Seattle Genetics, Daiichi Sankyo, Lilly, Merck Sharp&Dohme, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses, Hibercell, BioInvent, Gemoab, Gilead, Menarini, Zymeworks, Reveal Genomics, Scorpion Therapeutics, Expres2ion Biotechnologies, Jazz Pharmaceuticals, Abbvie, BridgeBio, Biontech, Biocon, Circle Pharma, Delcath Systems, Inc., Hexagon Bio; having received honoraria from Roche, Novartis, Eisai, Pfizer, Lilly, Merck Sharp&Dohme, Daiichi Sankyo, Astrazeneca, Gilead, Steamline Therapeutics; having received institutional research funding from Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer healthcare, Eisai, F.Hoffman-La Roche, Guardanth health, Merck Sharp&Dohme, Pfizer, Piqur Therapeutics,Iqvia, Queen Mary University of London; stock of MedSIR, MAJ3 Capital, Leuko (relative); having personal support for attending meetings and/or travel from Roche, Novartis, Eisai, Pfizer, Daiichi Sankyo, Astrazeneca, Gilead, Merck Sharp&Dhome, Steamline Therapeutics; and patents: Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A. ISSUED; Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy. Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/0338368 A1. LICENSED. The remaining authors declare no competing interests.